PP
FOMX

Paloma Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Paloma Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-92,200
Closed -$585K – 2261
2016
Q2 		$585K Buy
+92,200
New +$612K 0.01% 1462

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Paloma Partners's FOMX Position: Q3 2016 in Review

Paloma Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2016, closing a stake of 92,200 shares — an estimated $585K sold.

Paloma Partners first reported a position in FOMX in Q2 2016 and held it in 1 quarter. The position peaked at $585K in Q2 2016. 61 funds tracked by Wall St. Rank hold FOMX as of Q3 2016.

  • Paloma Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2016 after selling out during the quarter.
  • Paloma Partners sold 92,200 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2016, an estimated $585K.
  • Paloma Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2016 and held it in 1 quarter.
  • Paloma Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $585K in Q2 2016.
  • 61 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2016.

Based on Paloma Partners's 13F filing for Q3 2016, filed 14 Nov 2016.